Background: ZTI-01 (fosfomycin [FOS] for injection) has in vitro activity against Gram-positive andnegative organisms, including carbapenem-resistant Enterobacteriaceae. This activity, coupled with a primarily renal route of elimination, makes ZTI-01 a potentially favorable treatment for patients with cUTI. A PPK model, originally developed using Phase 1 data and an empirical relationship between FOS clearance (CLt) and creatinine clearance (CLcr) [Microbe 2017 Abstr. P1134], was refined using pooled data from healthy subjects and patients with cUTI, including acute pyelonephritis.
